BEIGENE's stock price surged 5.11% during intraday trading on Thursday, reflecting strong investor optimism following the release of the company's exceptional first-quarter financial results.

The biotechnology company reported a decisive turnaround to profitability, with net profit skyrocketing 178 times year-over-year to $227 million. Global revenue reached approximately $1.513 billion, representing a 35% increase compared to the same period last year. The performance was driven by robust sales growth of its core oncology products, Brukinsa (zanubrutinib) and Tislelizumab.

BEIGENE also reported significantly improved operating metrics, with adjusted operating profit rising 197% year-over-year to about $414 million and free cash flow increasing 14.03 times to $161 million. The company's raised full-year revenue and profit guidance further bolstered market confidence in its continued growth trajectory and global expansion.